Skip to main content

Advertisement

Table 1 Baseline characteristics of patients

From: Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy

Characteristics No. of patients (%)
All patients 244 (100)
Median age, years (min-max) 51.3 (26.6–75.6)
Stage
 I 111 (45.5)
 II 93 (38.1)
 III 40 (16.4)
Tumor size, ≤2 cm 49 (34.0)
Positive lymph nodes status 107 (43.9)
Tumor grade
 G1 18 (7.4)
 G2 143 (58.6)
 G3 59 (24.2)
 Unknown 24 (9.8)
Histology
 Ductal infiltrating carcinoma 212 (86.9)
 Other histology 32 (14.1)
Positive ER status (cut-off > 10%) 154 (63.1)
Positive PgRstatus(cut-off > 10%) 137 (56.1)
Ki67 positive status(cut-off > 14%) 112 (45.9)
Positive p53 status(cut-off ≥ 1%) 34 (13.9)
Positive HER2a(IHC/FISH) 26 (10.7)
Surgery
 Conservative 201 (82.4)
 Mastectomy 43 (17.6)
Adjuvant chemotherapy
 CMF 124 (50.8)
 FEC 120 (49.2)
Endocrine therapy 148 (60.6)
Radiotherapy 205 (84.0)
  1. aIHC 3 + or IHC 2+ and FISH amplified
  2. ER estrogen receptor; PgR, progesterone receptor
  3. CMF cyclophosphamide, methotrexate, 5-fluorouracil
  4. FEC 5-fluorouracil, epirubicin, cyclophosphamide